Drug Approvals

Iqirvo: A New Treatment for Primary Biliary Cholangitis

Iqirvo: A New Treatment for Primary Biliary Cholangitis

What is it prescribed for? Iqirvo,  Approved on June 10, 2024, is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.  What is the name of the drug and what does it do? Iqirvo (pronounced eye-KER-vo),...

Vafseo: A New Treatment for Anemia Due to Chronic Kidney Disease

Vafseo: A New Treatment for Anemia Due to Chronic Kidney Disease

What is it prescribed for? VAFSEO, Approved on March 27, 2024, is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. What is the name of the drug and what does it do? Vafseo (pronounced VAF-see-oh), (generic name: vadadustat), is a medication indicated for the treatment of...

Tevimbra: A New Treatment for Esophageal Squamous Cell Carcinoma

Tevimbra: A New Treatment for Esophageal Squamous Cell Carcinoma

What is it prescribed for? TEVIMBRA is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. Tevimbra was approved on March 13, 2024. What is the name of the drug and what does it do? Tevimbra (pronounced teh-VIM-brah), (generic...

A Powerful New Option: Zevtera Targets Serious Infections

A Powerful New Option: Zevtera Targets Serious Infections

What is it prescribed for? ZEVTERA, approved on April 3, 2024, is indicated for the treatment of:  Adult patients with Staphylococcus aureus bloodstream infections, including those with right-sided infective endocarditis,  Adult patients with acute bacterial skin and skin structure infections, and  Adult and pediatric patients (3 months to less than 18 years old)...

Aqneursa Offers New Hope in Niemann-Pick Disease Type C

Aqneursa Offers New Hope in Niemann-Pick Disease Type C

What is the name of the drug and what does it do? Aqneursa (pronounced ak-NUHR-sah), generic name levacetylleucine approved on September 25, 2024, is a medicine used to treat neurological symptoms of Niemann-Pick disease type C (NPC). NPC is a rare genetic disorder that affects the body’s ability to process cholesterol and fats, leading to severe brain and nerve...

Meet Sofdra: The Latest Topical Treatment for Excessive Sweating

Meet Sofdra: The Latest Topical Treatment for Excessive Sweating

What is it prescribed for? Sofdra, approved on June 18, 2024, is indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.  What is the name of the drug and what does it do? Sofdra (pronounced SOF-drah), (generic name: sofpironium bromide), is a medication used to treat primary axillary...